Inventiva S.A. (IVA)
NASDAQ: IVA · IEX Real-Time Price · USD
2.850
-0.190 (-6.25%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Company Description
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases.
Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.
Inventiva S.A.
| Country | France |
| Founded | 2011 |
| IPO Date | Jul 10, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 120 |
| CEO | Frederic Cren |
Contact Details
Address: 50 Rue De Dijon Daix, I0 21121 France | |
| Phone | 33380447500 |
| Website | inventivapharma.com |
Stock Details
| Ticker Symbol | IVA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $14.40 |
| CIK Code | 0001756594 |
| CUSIP Number | 46124U107 |
| ISIN Number | US46124U1079 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Frederic Cren | Co-Founder, Chief Executive Officer and Chairman |
| Dr. Pierre Broqua Ph.D. | Co-Founder, Chief Scientific Officer, Deputy Chief Executive Officer and Director |
| Jean Volatier | Deputy GM and Chief Financial Officer |
| Alice Roudot-Ketelers Pharm.D. | Chief Operating Officer |
| Eric Duranson L.L.M. | General Counsel |
| Nathalie Harroy | Head of Human Resources |
| Dr. Michael Cooreman | Chief Medical Officer |
| Pascaline Clerc Ph.D. | Executive Vice President of Strategy and Corporate Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 21, 2024 | 6-K | Report of foreign issuer |
| Jun 21, 2024 | 6-K | Report of foreign issuer |
| Jun 5, 2024 | 6-K | Report of foreign issuer |
| May 30, 2024 | 6-K | Report of foreign issuer |
| May 30, 2024 | 6-K | Report of foreign issuer |
| May 21, 2024 | 6-K | Report of foreign issuer |
| May 16, 2024 | 6-K | Report of foreign issuer |
| May 13, 2024 | 6-K | Report of foreign issuer |
| May 13, 2024 | 6-K | Report of foreign issuer |
| May 3, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |